

Visilizumab Biosimilar - Research Grade

Product Code: ICH5982

More Information

Species Reactivity: Human

Target: CD3E ϵ 1/2

Concentration: 5mg/ml

Isotype: IgG2 - kappa

Host: CHO Cells

product name H2: Visilizumab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P07766

Shipping Conditions: Blue ice

background: CD3 epsilon (CD3E) is an invariant component of the T-cell receptor complex and a foundational target in T-cell activation and immunotherapy research. This recombinant human IgG2 monoclonal is an unconjugated, non-therapeutic analog of visilizumab directed against CD3E and is supplied for research use only (RUO). The low-endotoxin preparation is suitable for in vivo studies and produced in scalable milligram to gram quantities for bulk and high-throughput laboratories. It is well suited to T-cell stimulation and binding assays, in vitro functional screening, control applications, and preclinical models of T-cell engagement and immune modulation.

Other names: CD3E, IMD18, T3E, TCRE, CD3e molecule, CD3epsilon, CD3 epsilon subunit of T-cell receptor complex

Purification Method: This monoclonal antibody was purified using Protein A



Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks